Drug intelligence / Profile preview

Radvax

Development stage: Phase 1
Lead developer: Vaxine
Modality: Vaccines & Immunotherapeutics
Administration: Intravenous, External Beam Radiotherapy

Overview

Radvax is a personalized autologous tumor vaccine developed by Vaxine Pty Ltd. It is formulated with an Advax adjuvant and is derived from a patient's own tumor tissue. The vaccine is being investigated in a Phase 1 clinical trial to assess its feasibility of preparation, safety, tolerability, and therapeutic response in patients with advanced solid cancers, either as a monotherapy or in combination with standard-of-care agents.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on Radvax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Radvax.

Explore the full profile